Hodgkin lymphoma

You are here: 

Prognosis and survival for Hodgkin lymphoma

If you have Hodgkin lymphoma (HL), you may have questions about your prognosis. A prognosis is the doctor’s best estimate of how cancer will affect someone and how it will respond to treatment. Prognosis and survival depend on many factors. Only a doctor familiar with your medical history, the type, stage and characteristics of your cancer, the treatments chosen and the response to treatment can put all of this information together with survival statistics to arrive at a prognosis.

A prognostic factor is an aspect of the cancer or a characteristic of the person that the doctor will consider when making a prognosis. A predictive factor influences how a cancer will respond to a certain treatment. Prognostic and predictive factors are often discussed together. They both play a part in deciding on a treatment plan and a prognosis.

The stage of HL is an important factor in determining prognosis and planning treatment. But how far the HL has spread and the organs or areas of tissue it affects can be different within each stage. So doctors use the following factors to help them estimate a prognosis for early and advanced HL. These factors are called unfavourable, or adverse, risk factors because they mean there is a greater risk that the HL will come back, or relapse, after it is treated.

Early Hodgkin lymphoma

Early HL includes stages 1 and 2. Doctors use the following risk factors to classify early HL as favourable or unfavourable:

  • Early favourable HL means that the person doesn’t have any of these risk factors.
  • Early unfavourable HL means that the person has one or more of these risk factors.

B symptoms

Doctors will add the letter A to the stage when the person doesn’t have B symptoms. The letter B means that the person has B symptoms. So early HL includes stages 1A, 1B and 2A.

B symptoms include:

  • unexplained fever of 38°C or higher
  • drenching night sweats
  • unexplained weight loss of more than 10% of body weight over the last 6 months

Tumour bulk

Bulky tumours often have a less favourable prognosis because they don’t tend to respond as well to treatment as smaller tumours. Doctors may describe the following as bulky:

  • a tumour in the chest that is at least one-third as wide as the chest
  • a tumour in another area of the body that is 10 cm or more across

Spread to areas other than the lymph nodes

HL that is only in lymph nodes has a more favourable prognosis than HL that has spread to other organs or areas of the body, such as the bone marrow, liver or lungs. (Doctors may refer to areas other than the lymph nodes as extranodal sites.)

Spread to several lymph node areas

HL that is in 3 or more areas of lymph nodes has a less favourable prognosis.

Erythrocyte sedimentation rate (ESR)

The following are unfavourable risk factors:

  • ESR of 50 mm/h or higher in people who don’t have B symptoms
  • ESR of 30 mm/h or higher in people who have B symptoms

Advanced Hodgkin lymphoma

Advanced HL includes stages 2B (B symptoms are present), 3 and 4. The International Prognostic Factors Project (IPFP) developed a prognostic score (IPS) for advanced HL based on the following 7 unfavourable, or adverse, risk factors.

Advanced favourable HL means that the person has 0–3 of these risk factors.

Advanced unfavourable HL means that the person has 4 or more of these risk factors.

Stage 4

Stage 4 HL has a less favourable prognosis than stage 2B or stage 3.

Older age

People who are 45 or older have a less favourable prognosis.

Male sex

Men have a less favourable prognosis than women.

Low hemoglobin levels

A hemoglobin level of less than 105 g/L is an unfavourable factor.

Low albumin levels

An albumin level of less than 40 g/L is an unfavourable factor.

High white blood cell count

A white blood cell (WBC) count of 15,000/mm3 or more is an unfavourable factor.

Low lymphocyte count

A lymphocyte count of less than 600/mm3 or less than 8% of the total WBC count is an unfavourable factor.


Dr Camilla Zimmermann Dr Camilla Zimmermann highlights the need to change the stigma of palliative care.

Learn more

Funding world-class research

Icon - paper

Cancer affects all Canadians but together we can reduce the burden by investing in research and prevention efforts. Learn about the impact of our funded research.

Learn more